Corporate Profile
Dedicated to providing safe and effective medicines,
Sihuan is a China-based, innovation-driven pharmaceutical group.
Our principal business activities encompass R&D, production, sales and marketing of proprietary medicines as well as generic drugs. We actively seek out drugs with strong market potential that will enhance and enlarge our portfolio. We have a strong portfolio of medicines that prevent, treat and cure diseases across a broad spectrum of therapeutic areas, and an exciting pipeline of promising new products in areas such as cardiovascular disease, hypertension, oncology, and diabetes.
We are widely recognised in China as a leading manufacturer of cardiocerebral vascular drugs, treating diseases of the heart, brain and blood vessels. While cardiocerebral vascular drugs are our main revenue drivers, our product line-up also includes a broad range of non-cardiocerebral vascular drugs that address areas such as cancer, bacterial infections, respiratory diseases and liver ailments. Several of Sihuan’s products are top-selling drugs in the segments that they compete in.
Sihuan’s emphasis on R&D drives our product development pipeline, adding to our competitive edge. Focusing on the healthcare needs of the community, we continually invest in state-of-the-art R&D capabilities to ensure that we remain relevant, effective and on the cutting edge of international standards. To maximise returns, we have our own production facilities for key products, and tap on the strengths of third-party contract manufacturers for our other drugs.
We adopt a robust business model, effectively marketing our products through an extensive network of distributors and collecting payment on a cash-on-delivery basis for most of our sales. Our comprehensive sales and marketing network ensures that communities across China have access to our quality medicines and that we are best able to understand and respond to their healthcare needs.
At
Sihuan, we constantly seek to improve the way we do business to ensure that we deliver the value our customers need and our shareholders deserve. This means we listen to the views of the people involved in healthcare decisions and we are open to collaborations where they optimise our efficiency and effectiveness.
Group Structure
